Cáncer de piel tipo melanoma

+ -Text Size

Otros recursos y referencias TEMAS

Referencias: guía detallada del cáncer de piel tipo melanoma

American Academy of Pediatrics. Policy statement – Ultraviolet radiation: A hazard to children and adolescents. Pediatrics. 2011;127:588-597.

American Cancer Society. Cancer Facts & Figures 2015. Atlanta, Ga: American Cancer Society; 2015.

American Joint Committee on Cancer. Melanoma of the skin. In: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010:325-344.

Berman B, Villa AM. Immune response modulators in the treatment of skin cancer. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, eds. Cancer of the Skin. Philadelphia, Pa: Elsevier Saunders; 2005:499-513.

Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. New Engl J Med. 2005;353:2135-2147.

Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.

El Ghissassi, Baan R, Straif K, et al. A review of human carcinogens – part D: Radiation. Lancet Oncol. 2009;10:751-752.

Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-703.

Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107-114.

Freedman DM, Miller BA, Tucker MA. New Malignancies Following Melanoma of the Skin, Eye Melanoma, and Non-melanoma Eye Cancer. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publ. No. 05-5302. Bethesda, MD, 2006. Accessed on 4/18/2014 at http://seer.cancer.gov/archive/publications/mpmono/MPMonograph_complete.pdf.

Gangadhar TC, Fecher LA, Miller CJ, et al. Chapter 69: Melanoma. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

Hamid O, Robert C, Daud A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-144.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.

Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial. JAMA. 2014;312:1744-1753.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER website, April 2014.

Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc. 2012;87:991-1003.

Kushi LH, Doyle C, McCullough M, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62:30-67.Leachman SA, Lowstuter K, Wadge LM. Genetic testing for melanoma. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, eds. Cancer of the Skin. Philadelphia, Pa: Elsevier Saunders; 2005:281-290.

National Cancer Institute. Physician Data Query (PDQ). Melanoma Treatment. 2014. Accessed at www.cancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional on December 30, 2014.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Melanoma. Version 1.2015. Accessed at www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf on December 30, 2014.

Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: A meta-analysis of pigmentary characteristics and freckling. Int J Cancer. 2010;127:2430-2445.

Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-924.

Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.

Slingluff CL, Flaherty K, Rosenberg SA, Read PW. Cutaneous melanoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1643-1691.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.

Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.

Fecha de última actualización: 05/13/2015
Fecha de último cambio o revisión: 05/13/2015